XCEPTOR PAIN- menthol cream United States - English - NLM (National Library of Medicine)

xceptor pain- menthol cream

xceptor llc - methyl salicylate  10% - topical analgesic topical pain relief for minor aches and pains.

XCEPTOR CBD PAIN MENTHOL- methyl salicylate cream United States - English - NLM (National Library of Medicine)

xceptor cbd pain menthol- methyl salicylate cream

xceptor llc - methyl salicylate  10% - topical analgesic topical pain relief for minor aches and pains.

XCEPTOR CBD PAIN LAVENDER- tea salicylate cream United States - English - NLM (National Library of Medicine)

xceptor cbd pain lavender- tea salicylate cream

xceptor llc - tea salicylate  10% - topical analgesic topical pain relief for minor aches and pains.

XCEPTOR CBD PAIN UNSCENTED- tea salicylate cream United States - English - NLM (National Library of Medicine)

xceptor cbd pain unscented- tea salicylate cream

xceptor llc - tea salicylate  10% - topical analgesic topical pain relief for minor aches and pains.

XCEPTOL PAIN UNSCENTED- tea salicylate cream United States - English - NLM (National Library of Medicine)

xceptol pain unscented- tea salicylate cream

xceptor llc - tea salicylate  10% - topical analgesic topical pain relief for minor aches and pains.

CELLCEPT mycophenolate mofetil 500 mg tablet blister pack (new formulation) Australia - English - Department of Health (Therapeutic Goods Administration)

cellcept mycophenolate mofetil 500 mg tablet blister pack (new formulation)

roche products pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; purified talc; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; hyprolose; iron oxide red; macrogol 400 - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

CELLCEPT mycophenolate mofetil 250mg capsule Australia - English - Department of Health (Therapeutic Goods Administration)

cellcept mycophenolate mofetil 250mg capsule

roche products pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: povidone; titanium dioxide; iron oxide yellow; iron oxide red; croscarmellose sodium; gelatin; pregelatinised maize starch; indigo carmine; magnesium stearate - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

CELLCEPT 250 MG Israel - English - Ministry of Health

cellcept 250 mg

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - capsules - mycophenolate mofetil 250 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

CELLCEPT 500 MG Israel - English - Ministry of Health

cellcept 500 mg

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

CELLCEPT mycophenolate mofetil 200mg/mL suspension bottle Australia - English - Department of Health (Therapeutic Goods Administration)

cellcept mycophenolate mofetil 200mg/ml suspension bottle

roche products pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: citric acid; xanthan gum; aspartame; methyl hydroxybenzoate; purified water; silicon dioxide; sorbitol; lecithin; sodium citrate dihydrate; flavour - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.